Comparison and enlightenment of anti-infective medicines between WHO model list of essential medicines for children， essential medicine list of WHO and national essential medicine list

DONG Tu; MA Xin; MA Shuli; LIU Wei

doi:10.6039/j.issn.1001-0408.2023.11.02

您当前的位置：

首页 >

文章列表页 >

Comparison and enlightenment of anti-infective medicines between WHO model list of essential medicines for children， essential medicine list of WHO and national essential medicine list

更新时间：2023-06-09

- Comparison and enlightenment of anti-infective medicines between WHO model list of essential medicines for children， essential medicine list of WHO and national essential medicine list
- ZHONGGUO YAOFANG Vol. 34, Issue 11, Pages: 1293-1297(2023)
- 作者机构：
  
  1.郑州大学药学院，郑州　450001
  2.河南省药品审评查验中心，郑州　450008
  3.郑州大学附属儿童医院药学部，郑州　450012
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.11.02
  CLC： R985;R978
- Published：15 June 2023，
  
  Received：20 October 2022，
  
  Revised：12 March 2023，
扫描看全文
董途,马鑫,马姝丽等.WHO儿童基本药物示范目录、WHO和我国基本药物目录中抗感染药物的比较与启示 ^Δ[J].中国药房,2023,34(11):1293-1297.

DONG Tu,MA Xin,MA Shuli,et al.Comparison and enlightenment of anti-infective medicines between WHO model list of essential medicines for children， essential medicine list of WHO and national essential medicine list[J].ZHONGGUO YAOFANG,2023,34(11):1293-1297.
董途,马鑫,马姝丽等.WHO儿童基本药物示范目录、WHO和我国基本药物目录中抗感染药物的比较与启示 ^Δ[J].中国药房,2023,34(11):1293-1297. DOI： 10.6039/j.issn.1001-0408.2023.11.02.

DONG Tu,MA Xin,MA Shuli,et al.Comparison and enlightenment of anti-infective medicines between WHO model list of essential medicines for children， essential medicine list of WHO and national essential medicine list[J].ZHONGGUO YAOFANG,2023,34(11):1293-1297. DOI： 10.6039/j.issn.1001-0408.2023.11.02.

摘要

目的

为丰富我国儿童抗感染药物用药选择、促进我国儿童基本药物目录的建立提供建议和参考。

方法

采用描述性分析法，从药物类别、品种、剂型、规格和符号标记等方面对比研究《WHO儿童基本药物示范目录》（EMLc）、《WHO基本药物目录》（EML）与我国《国家基本药物目录》（NEML）中抗感染药物的异同。

结果

EMLc中的抗感染药物均被EML覆盖（占EML的85.3%）。NEML中抗感染药物的药物信息相对欠缺，新品种较少，如未收录EMLc中第三代及以上头孢菌素，剂型也相对局限（主要为片剂、胶囊和注射剂），但规格较为丰富。

结论

参考EMLc，从年龄、体质量、联合用药等方面增加我国基本药物的儿童用药指导，增加NEML中口服液体制剂、刻痕片等儿童适用剂型；在更新NEML时纳入头孢克肟、达卡他韦等儿童适宜的较新品种；参照EML与EMLc的承接性，基于NEML建立我国儿童基本药物目录，以满足儿童用药需求，促进儿童药物安全使用。

Abstract

OBJECTIVE

To provide suggestions and reference for enriching the selection of anti-infective medicines for children in China and promoting the establishment of the Essential Medicine List for Children in China.

METHODS

Descriptive analysis method was used to statistically compare the differences and similarities of anti-infective medicines included in the

World Health Organization Model List of Essential Medicines for Children

（EMLc），

World Health Organization Model List of Essential Medicines

（EML） and

National Essential Medicine List

（NEML） in terms of drug category， variety， dosage form， specification， symbol mark， etc.

RESULTS

All anti-infective medicines of EMLc were covered by EML （85.3%）. NEML lacked the information of anti-infective medicines relatively， and contained few new categories； for example， the third-generation and above cephalosporins in EMLc were not included， and the drug dosage forms were also relatively limited （mainly tablets， capsules and injections）， but the specifications were relatively rich.

CONCLUSIONS

With reference to EMLc， the guidance on the use of essential medicines for children in China should be added from the aspects of age， body weight， combined medication， etc.， and the dosage forms suitable for children such as oral liquid preparations and scored tablets should be added to NEML； when updating the NEML the newer drugs suitable for children such as cefixime and dacatavir should be included. Finally， with reference to the continuity of EML and EMLc， the Essential Medicine List for Children in China should be established based on NEML to meet the drug needs of children and promote the safe use of drugs in children.

关键词

抗感染药物基本药物目录儿童用药世界卫生组织

Keywords

Essential Medicine Listmedicine use of childrenWHO

references

国家卫生健康委员会. 关于就《国家基本药物目录管理办法（修订草案）》公开征求意见的公告[EB/OL].（2021-11-15）[2022-10-17]. http：//www.nhc.gov.cn/yaozs/s7656/202111/068c31b85cb7486b9f77057b3e358aae.shtmlhttp://www.nhc.gov.cn/yaozs/s7656/202111/068c31b85cb7486b9f77057b3e358aae.shtml.

荣红国，李琪，董玥，等.基于政策工具的我国儿童用药政策分析[J].中国药房，2022，33（14）：1665-1670.

World Health Organization. WHO model list of essential medicines for children：8th list[EB/OL].（2021-09-30）[2022-10-17]. https：//www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.03.

World Health Organization. WHO model lists of essential medicines[EB/OL]. （2021-09-30）[2022-10-17]. https：//www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02.

国家卫生健康委员会. 关于印发国家基本药物目录（2018年版）的通知[EB/OL].（2018-10-25）[2022-10-17]. http：//www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a- 3940d08d996b588d941631.shtmlhttp://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a-3940d08d996b588d941631.shtml.

万杰，关奇. 头孢地尔（Cefiderocol，Fetroja）[J].中国药物化学杂志，2020，30（8）：514.

王雨，刘笑芬. 美国FDA批准Zemdri（plazomicin）治疗成人复杂性尿路感染[J].中国感染与化疗杂志，2019，19（4）：370.

World Health Organization. Global health estimates：lea- ding causes of death[EB/OL].（2020-12） [2023-03-08]. https：//cdn.who.int/media/docs/default-source/gho-docu- ments/global-health-estimates/ghe2019_cod_methods.pdf?sfvrsn=37bcfacc_5https://cdn.who.int/media/docs/default-source/gho-docu-ments/global-health-estimates/ghe2019_cod_methods.pdf?sfvrsn=37bcfacc_5.

徐欠欠，刘艳.伏立康唑治疗儿童侵袭性肺部真菌感染疗效观察[J].儿科药学杂志，2021，27（9）：12-15.

王叨，汤苗苗，丁艳杰，等. 伏立康唑干混悬剂防治儿童异基因造血干细胞移植术期间侵袭性真菌感染的临床研究[J].中华实用儿科临床杂志，2022，37（5）：343-347.

国家药品监督管理局. 国家药品不良反应监测年度报告：2021年[EB/OL].（2022-03-30）[2023-03-08]. https：//www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20220329161925106.htmlhttps://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20220329161925106.html.

WIRTZ V J，HOGERZEIL H V，GRAY A L，et al. Essential medicines for universal health coverage[J]. Lancet，2017，389（10067）：403-476.

崔兆涵，吕兰婷.国家药物政策框架构建下的我国药物政策改革逻辑分析与研究：基于2009－2019年的药物政策文本分析[J].中国药房，2019，30（14）：1873-1880.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative analysis of domestic classification management list for clinical use of antibiotics versus WHO AWaRe classification list of antibiotics

江苏省基本药物可获得性实证研究

基本药物制度的相关研究进展

我国基本药物遴选原则及遴选方法浅析

我国儿童基本药物政策框架设计

Related Author

YANG Yaoyao

LING Kexin

ZHANG Xi

DU Kexin

ZHANG Wanmeng

HU Lin

ZHENG Bo

GUAN Xiaodong

Related Institution

Dept. of Pharmacy Administration and Clinical Pharmacy， School of Pharmaceutical Sciences， Peking University

Institute of Clinical Pharmacology， Peking University First Hospital

International Research Center for Medicinal Administration， Peking University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰